The escalating threat of antibiotic resistance demands faster, more accurate diagnostic tools. A new method utilizing nanopore sequencing promises to dramatically reduce the time it takes to identify antibiotic resistance in bacteria – from days to hours. This breakthrough offers a potential game-changer in the fight against infections increasingly resistant to treatment, offering clinicians the ability to make more informed decisions and prescribe targeted therapies sooner.
Researchers have developed a streamlined protocol, dubbed s5PSeq, that leverages the speed and portability of nanopore sequencing technology. This approach allows for rapid phenotypic antimicrobial sensitivity testing, essentially determining which antibiotics will be effective against a specific bacterial strain. The ability to quickly pinpoint effective treatments is crucial in combating the spread of antibiotic resistance, a global health crisis estimated to cause at least 1.27 million deaths annually, according to the Centers for Disease Control and Prevention .
The core innovation lies in the compatibility of s5PSeq with portable Nanopore sequencing devices, which are becoming increasingly common in diagnostic and research laboratories. “Faster, phenotypic diagnostics are essential if we are to address antibiotic resistance effectively. Our method shows that reliable molecular readouts can be obtained in hours rather than days,” explains Vicent Pelechano, senior researcher at MTC and SciLifeLab, and senior author of the study published in Cell Reports Methods in March 2026.
Nanopore sequencing works by threading DNA strands through tiny pores, measuring changes in electrical current to identify the genetic code. This technology allows for the reading of ultra-long DNA fragments, providing a more complete picture of the bacterial genome and its resistance mechanisms. The researchers found that sequencing success was highest when using 12- or 24-plex runs – processing 12 or 24 samples simultaneously – with DNA input of 100 nanograms or less. Higher multiplexing levels (36-plex) and greater DNA input significantly reduced performance, highlighting the importance of optimized workflows for bacterial whole-genome sequencing.
Currently, antibiotic susceptibility testing often relies on traditional culture-based methods, which can take 24 to 72 hours, or even longer, to yield results. This delay can lead to the inappropriate use of broad-spectrum antibiotics, contributing to the development and spread of resistance. S5PSeq offers a significant reduction in turnaround time, potentially enabling clinicians to initiate targeted therapy much sooner.
Adapting s5PSeq for Real-World Clinical Use
The research team is now focused on adapting s5PSeq for direct testing of complex patient samples, eliminating the need for prior bacterial culturing. This would further streamline the process and reduce the time to diagnosis. In collaboration with Karolinska University Hospital, they are also expanding the method to encompass a wider range of pathogens and antibiotics, evaluating its potential in diverse clinical settings.
“Our next step is to understand how well the method performs outside controlled laboratory conditions,” says Honglian Liu, PhD at Karolinska Institutet and first author of the study. “These ongoing studies will help determine how s5PSeq can support faster and more informed treatment decisions.” A study published in Frontiers in Public Health in February 2026 also highlighted the potential of nanopore sequencing to overcome cost and infrastructure barriers in low-resource settings, making rapid AMR surveillance more accessible globally.
The Future of AMR Surveillance
The development of s5PSeq represents a significant step forward in the ongoing battle against antibiotic resistance. Although further validation and implementation studies are needed, the promise of rapid, accurate, and accessible diagnostic tools offers a beacon of hope in addressing this critical public health challenge. The ability to quickly identify resistance mechanisms will not only improve patient outcomes but also inform public health strategies aimed at curbing the spread of resistant bacteria.
As research continues, the integration of nanopore sequencing into routine clinical workflows could become a standard practice, empowering healthcare professionals to make more informed decisions and ultimately save lives. The ongoing function to refine and expand the s5PSeq method underscores the commitment to innovation in the face of a growing global threat.
What are your thoughts on the potential of rapid sequencing technologies to combat antibiotic resistance? Share your comments below.
Disclaimer: This article provides informational content and should not be considered medical advice. Always consult with a qualified healthcare professional for diagnosis and treatment of any medical condition.
